Gene
ABL1
ABL1 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (15), Actionable biomarkers (27), Trial mentions (762), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention ABL1. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers. Not plotted: 3 with a planned future start and 7 with no date at all.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 3 dated before 1990 and 17 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 54 of 8,738 | 0.62% | not measured | |
| 2025 | 47 of 8,875 | 0.53% | not measured | |
| 2024 | 54 of 8,597 | 0.63% | not measured | |
| 2023 | 32 of 8,275 | 0.39% | 34 of 11,460 | 0.30% |
| 2022 | 37 of 8,285 | 0.45% | 48 of 13,598 | 0.35% |
| 2021 | 41 of 8,692 | 0.47% | 59 of 15,045 | 0.39% |
| 2020 | 37 of 7,640 | 0.48% | 53 of 14,459 | 0.37% |
| 2019 | 47 of 7,300 | 0.64% | 49 of 12,159 | 0.40% |
| 2018 | 40 of 6,927 | 0.58% | 47 of 11,854 | 0.40% |
| 2017 | 41 of 6,558 | 0.63% | 64 of 11,595 | 0.55% |
Showing 10 of 37 years.
Assay-provider ledger (15)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Moroccan Foundation for Advanced Science Innovation and Research (MASCIR) | Not a company | Clinical validationAnalytical validation | 1 | July 01, 2026 |
| ArcherDX | Unclassified | Clinical validationAnalytical validation | 1 | February 01, 2019 |
| Illumina | Unclassified | Clinical validationAnalytical validation | 2 | February 01, 2019 |
| QIAGEN | Reagent supplier | Clinical validationAnalytical validation | 2 | February 01, 2019 |
| RainDance Technologies | Reagent supplier | Clinical validationAnalytical validation | 1 | February 01, 2019 |
Showing 5 of 15 assay-provider companies.
Actionable biomarkers (27)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| ABL1-BCR fusion | Dasatinib | response-associated | acute lymphoblastic leukemia | Cancer Genome Interpreter |
| ABL1-BCR fusion | Venetoclax | response-associated | acute lymphoblastic leukemia | Cancer Genome Interpreter |
| ABL1 (T315I) | Ponatinib | response-associated | acute lymphoblastic leukemia | Cancer Genome Interpreter |
| ABL1-BCR fusion | Ponatinib | response-associated | acute lymphoblastic leukemia | Cancer Genome Interpreter |
| ABL1-BCR fusion | Imatinib | response-associated | acute lymphoblastic leukemia | Cancer Genome Interpreter |
Showing 5 of 27 actionable-biomarker assertions.
Trial mentions (762)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT01215487 | Trial biospecimen (AACT) |
| NCT00052520 | Trial eligibility (AACT) |
| NCT04544592 | Trial eligibility (AACT) |
| NCT03249870 | Trial eligibility (AACT) |
| NCT01657604 | Trial eligibility (AACT) |
Showing 5 of 762 trial mentions.
Target-disease associations (693)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| ATTRV122I amyloidosis | cardiovascular disease | Mouse knockout (IMPC) |
| Abnormal skeletal morphology | phenotype | Variant curation (ClinVar / EVA) |
| Abnormality of the skeletal system | phenotype | GWAS credible sets |
| Acute Leukemia | cancer or benign tumor | Literature (Europe PMC) |
| Adenoid Cystic Breast Carcinoma | cancer or benign tumor | Cancer Gene Census |
Showing 5 of 693 associations.
Vendor sourcing (2,709)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The variant is not observed in the gnomAD v2.1.1 dataset. Predicted Consequence/Location: Missense variant In silico tool predictions suggest damaging effect... | View ClinVar record SCV002012192.2 |
| A&D Instruments, Ltd | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | (non-exclusive; when CRP test is unavailable in medical records) associated with high or very high cardiovascular (CV) toxicity risk factors (according to th... | View trial NCT06778122 |
| A&D Instruments, Ltd | Trial collaborator | Mentioned in trial textTrial free-text mention | ABL | View trial NCT06778122 |
| ADIR, a Servier Group company | Trial collaborator | Named in trial exclusion criteriaTrial eligibility criteria | : * Mature B-cell ALL ; Philadelphia chromosome-positive (Ph+) or BCR-ABL1-positive ALL * Preexisting known coagulopathy ; * History of pancreatitis; * Cont... | View trial NCT04067518 |
| ADIR, a Servier Group company | Trial collaborator | Mentioned in trial textTrial free-text mention | ABL1 | View trial NCT04067518 |
Showing 5 of 2,709 sourcing records.
Trial-cited literature (938)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Molecular characterization and predictors of relapse in patients with Ph + ALL after frontline ponatinib and blinatumomab. | Journal of hematology & oncology | 2025 | 22 |
| A Phase I/II Trial of Ruxolitinib with Chemotherapy for Patients with Relapsed and/or Refractory Philadelphia-like Acute Lymphoblastic Leukemia. | Clinical lymphoma, myeloma & leukemia | 2025 | 8 |
| Identification of anticancer drugs associated to cancer therapy-related cardiac dysfunction: a VigiBase® disproportionality analysis. | European heart journal. Cardiovascular pharmacotherapy | 2025 | 3 |
| Outcome of children with B-cell acute lymphoblastic leukemia with hypodiploidy or BCR::ABL1 fusion undergoing allogeneic HSCT. | Blood | 2025 | 2 |
| Measuring treatment burden related to general practice in patients with multimorbidity: development and validation of a PROM. | Family medicine and community health | 2025 | 2 |
Showing 5 of 938 papers.
Protein variant mentions (48)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A337T | 1 | 2015 | PMID 25741868 |
| p.A433T | 1 | 2015 | PMID 25741868 |
| p.E1037Q | 1 | 2015 | PMID 25741868 |
| p.E255Q | 1 | 2013 | PMID 23468307 |
| p.E255V | 11 | 2010 to 2025 | PMID 40369607, PMID 37738125, PMID 35643868 |
Showing 5 of 48 variants.
Literature-extracted relations (422)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Levofloxacin | Chemical | associate |
Clinical evaluation of a commercial culture-free targeted next-generation sequencing test for diagnosis of drug-resistant tuberculosis. | 2025 |
| DASATINIB | Chemical | negative_correlate |
Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372/COG AALL1122): a single-arm, multicentre, phase 2 trial. | 2023 |
| DASATINIB | Chemical | negative_correlate |
Low-Dose Dasatinib (50 mg Daily) Frontline Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: 5-Year Follow-Up Results. | 2023 |
| Imatinib | Chemical | negative_correlate |
Ponatinib, chemotherapy, and transplant in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. | 2022 |
| DASATINIB | Chemical | negative_correlate |
Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients. | 2021 |
Showing 5 of 422 relation assertions.
Organizations publishing (574)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| The University of Texas System | Academic | 59 | 2002 to 2025 |
| Memorial Sloan Kettering Cancer Center | Hospital | 34 | 2000 to 2022 |
| Dana-Farber Cancer Institute | Other | 32 | 2000 to 2023 |
| Novant Health | Hospital | 32 | 2002 to 2023 |
| Government of the United States of America | Government | 25 | 1998 to 2023 |
Showing 5 of 574 organizations.
Where ABL1 appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- injury, poisoning or other complication
- integumentary system disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- reproductive system or breast disease
- respiratory or thoracic disease
- urinary system disease
586 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.